Myasthenia Gravis Treatment Market Dynamic Demand For Future Growth, Global Industry Analysis by Size, Top Major Companies, Market Share and Regional Forecast to 2027
Myasthenia gravis (MG) is a type of chronic autoimmune neuromuscular disease which causes weakness in skeletal muscles in the arms and legs. Double vision, facial paralysis, difficulty in walking, dropping of eyelids, are symptoms of myasthenia gravis. This disease is diagnosed by tests such as repetitive nerve stimulation test, blood test for antibodies, edrophonium test, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI). Corticosteroids drugs (azathioprine, and cyclosporine) and Acetylcholine esterase inhibitors (Edrophonium, and Pyridostigmine) are used for the treatment of MG.
Get FREE Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables, and Figures) of Myasthenia Gravis Treatment Market, https://www.coherentmarketinsights.com/insight/request-sample/2625
Myasthenia Gravis Treatment Market Drivers
Consistent research and development activities are expected to propel growth of the myasthenia gravis treatment market. For instance, in October 2017, Alexion Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration for Soliris which contains eculizumab as an active component. This drug is used for treatment of antibody positive generalized myasthenia gravis, and it is also used in treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS).
Furthermore, increasing number of clinical trials for treatment of myasthenia gravis are expected to drive the myasthenia gravis treatment market growth. For instance, in December 2017, Novartis AG initiated phase II clinical trial of CFZ533 for treatment of severe myasthenia gravis. The main function of CFZ533 is the modification of immune response by deactivation of white blood cells. Hence, it is expected to help with improvement and management of severe myasthenia gravis.
Moreover, Argenx BVBA is conducting a clinical phase III study of ARGX-113 for treatment of generalized myasthenia gravis. ARGX-113, also named Efgartigimod, is administered intravenously. The study started in March 2019 and is expected to complete in June 2021.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2625
Myasthenia Gravis Treatment Market Restraints
Side effects of the drugs used for treating myasthenia gravis are expected to hamper growth of the myasthenia gravis treatment market. For instance, according to BioNews Services, LLC report, in April 2019, high dose combination of cholinesterase inhibitors (ChEIs) and calcineurine inhibitors (CNIs) such as Mestinon and Prograf are responsible for severe muscle cramps in myasthenia gravis patients. Hence, this factor is expected to hinder growth of the myasthenia gravis treatment market.
Myasthenia Gravis Treatment Market- Regional Analysis
On the basis of region, the global myasthenia gravis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold a dominant position in the myasthenia gravis treatment market over the forecast period. This is owing to increasing incidence and prevalence of myasthenia gravis in the U.S. For instance, in October 2018, according to the National Center for Biotechnology Information (NCBI), incidence of myasthenia gravis was around 5 to 30 cases per million person years and prevalence is around 10 to 20 cases per 100,000 population in U.S.
Got any Query? Feel free to ask us at : https://www.coherentmarketinsights.com/insight/talk-to-analyst/2625
Furthermore, Asia Pacific is projected to witness significant growth in the global myasthenia gravis treatment market, owing to increasing research and development activities for treatment of myasthenia gravis. For instance, Sun Yat-Sen University in China is conducting phase III clinical trial of Azathioprine and Leflunomide for treatment of myasthenia gravis. The study started in September 2012, and is expected to complete in January 2020.
Key players operating in the myasthenia gravis treatment market are Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Valeant Pharmaceutical International, Inc. Alexion Pharmaceutical Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International, Inc., Shire plc, and Avadel Pharmaceutical, PLC.
To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/2625
Myasthenia Gravis Treatment Market –Taxonomy
- Cholinesterase Inhibitors
- Intravenous immunoglobulin (IVIg)
- Monoclonal Antibody
By Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Have a Look at Related Research Insights:
Achondroplasia Treatment Market, By Drug Class (Lipase Inhibitor, Human Growth Hormone And Appetite Suppressants), By Distribution Channel (Hospitals Pharmacies, Speciality Clinics, Online Pharmacy, And Retail Pharmacy), By Patient Type (Adult And Paediatric), And By Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) – Size, Share Outlook, and Opportunity Analysis, 2020 – 2027
Vascular Injury Treatment Market, by Device (Instruments and Consumables), by Injury Type (Spasm, Thrombosis, Arteriovenous (AV) Fistula, Contusion/Intimal Flap, and Others), by End Users (Ambulatory Surgical Centers, Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire